The company said the decision was made “based on a review of the data available at this time,” and said it would say no more “in order to protect the integrity of ongoing registrational studies.” Leerink analyst Seamus Fernandez said the development was a “clear setback for BMY,” especially given a fall approval by rival drugmaker Merck in first-line lung cancer.